Breast Cancer and HER2-negative breast cancer
GBG Forschungs GmbH focuses on clinical research in breast cancer, with particular attention to HER2-negative disease and patients at elevated risk of relapse after standard neoadjuvant treatment. Its work includes studies in early-stage and high-risk settings, where treatment strategies are aimed at improving disease control and reducing recurrence.
- HER2-negative breast cancer
- High relapse-risk disease
- Primary high-risk lobular breast cancer
The sponsor’s research activity also extends to invasive disease-free survival and pathological complete response as key clinical endpoints in early breast cancer.
Hormone Receptor-positive and HER2-positive breast cancer
The sponsor is active in hormone receptor-positive breast cancer, including combinations of endocrine treatment with targeted agents in both early and locally advanced disease. Its portfolio includes research in HER2-positive, HR-positive, PIK3CA-mutant breast cancer, reflecting interest in biologically defined subgroups.
- HR-positive, HER2-positive early breast cancer
- PIK3CA-mutant disease
- Endocrine-based treatment combinations
These studies place emphasis on treatment approaches that integrate endocrine therapy with targeted inhibition in early breast cancer.
Locally Advanced and Metastatic Breast Cancer
GBG Forschungs GmbH also supports research in locally advanced and metastatic breast cancer, especially in patients with HR-positive, HER2-negative disease and gBRCA1/2 mutations. This area reflects a therapeutic interest in advanced disease management and biomarker-driven treatment selection.
- Locally advanced breast cancer
- Metastatic breast cancer
- gBRCA1/2-mutated disease
The sponsor’s trials in this area examine combinations involving oral SERD therapy and PARP inhibition for molecularly selected patients.
Targeted Therapy in Early and High-risk Disease
A major theme in the sponsor’s research is the use of targeted therapy in early breast cancer, including agents directed at PI3K, AKT, estrogen receptor, and HER2 pathways. These studies are concentrated in patients with aggressive or biologically distinct breast cancer subtypes.
- PI3K pathway inhibition
- AKT pathway inhibition
- Selective estrogen receptor degradation
Research in this domain includes neoadjuvant and adjuvant treatment settings for high-risk breast cancer and lobular breast cancer.
